Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
Investigation of ceftazidime-avibactam susceptibility in clinical isolates of gram-negative bacteria
thumbnail.default.placeholder
Tarih
2022-01-01
Yazarlar
Dumlu, Ridvan
Uyar, Neval Yurttutan
Ayas, Meltem
Aksoy, Nilay
Ozturk, Nur
Kocagoz, Ayse Sesin
Süreli Yayın başlığı
Süreli Yayın ISSN
Cilt Başlığı
Yayınevi
Scientific and Technological Research Council Turkey
Dergi Adı
TURKISH JOURNAL OF MEDICAL SCIENCES
Özet
Background/aim: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples. Materials and methods: Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in Acibadem Healthcare Group hospitals
ceftazidime-avibactam susceptibility results were evaluated using a 10/4 mu g (Oxoid, UK) disc and evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively investigated and statistically analyzed using SPSS 25.0. Results: Male patients made up 52\% (n = 581) of the study's total patient population, and they averaged 55.5 +/- 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4\%) were sensitive to ceftazidime-avibactam. An increased risk of resistance was observed with female gender (OR = 2.29
CI 95\% {[}1.45-3.61]
p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95\% {[}1.03-2.7]
p < 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95\% {[}2.47-6.7]
p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI) 95\% {[}9.9-14.7]]
p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95\% {[}1.22-2.93]
p < 0.05). Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6\%, and it was thought that resistant strains produced metallo-beta-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment.
ceftazidime-avibactam susceptibility results were evaluated using a 10/4 mu g (Oxoid, UK) disc and evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively investigated and statistically analyzed using SPSS 25.0. Results: Male patients made up 52\% (n = 581) of the study's total patient population, and they averaged 55.5 +/- 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4\%) were sensitive to ceftazidime-avibactam. An increased risk of resistance was observed with female gender (OR = 2.29
CI 95\% {[}1.45-3.61]
p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95\% {[}1.03-2.7]
p < 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95\% {[}2.47-6.7]
p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI) 95\% {[}9.9-14.7]]
p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95\% {[}1.22-2.93]
p < 0.05). Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6\%, and it was thought that resistant strains produced metallo-beta-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment.
Açıklama
Anahtar kelimeler
Antimicrobial agents, drug-resistant, multidrug-resistant, ceftazidime-avibactam combination, gram-negative bacteria